By Katherine Hamilton
Gilead Sciences posted results from a Phase 3 trial showing its HIV treatment was effective.
The trial of bictegravir 75 mg/lenacapavir 50 mg was also well-tolerated and demonstrated the potential to broaden into options for adults with virological suppression, the company said.
The Foster City, Calif., company said the treatment offered comparable efficacy to Biktarvy and treatment with complex multi-tablet regimens.
"We look forward to working with regulatory authorities to potentially bring this combination forward to people with HIV," said Jared Baeten, Gildead's virology therapeutic head.
Bictegravir and lenacapavir in combination are investigational and not approved anywhere globally.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 25, 2026 14:08 ET (19:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.